|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
gptkb:railway_station
|
|
gptkbp:affects
|
gastric acid secretion
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1988
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
gptkb:Prilosec
gptkb:Losec
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to omeprazole
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
20 mg once daily
40 mg once daily
omeprazole magnesium 20 mg once daily
omeprazole sodium 40 mg once daily
|
|
gptkbp:formulation
|
gptkb:beer
gptkb:tablet
suspension
injectable solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
omeprazole
|
|
gptkbp:ingredients
|
C17 H19 N3 O3 S
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
gptkb:clopidogrel
gptkb:warfarin
gptkb:diazepam
|
|
gptkbp:is_atype_of
|
A02 B C01
|
|
gptkbp:is_available_on
|
gptkb:drug
prescription medication
|
|
gptkbp:is_used_for
|
treating gastroesophageal reflux disease (GERD)
treating peptic ulcers
treating Zollinger-Ellison syndrome
|
|
gptkbp:lifespan
|
0.5 to 1 hour
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Prilosec_OTC
Zegerid
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
diarrhea
|
|
gptkbp:storage
|
room temperature
protected from light
protected from moisture
|
|
gptkbp:type_of
|
73590-58-6
|
|
gptkbp:bfsParent
|
gptkb:Prilosec_OTC
gptkb:Nexium
|
|
gptkbp:bfsLayer
|
4
|